Contents

Preface ix

PART I PROPERTY AND PROGRESS
1. Rising Expectations—and Diminishing Returns 3
2. Property Generally: Externalities, Coordination, and the Public Domain 13

PART II MAINTAINING THE PUBLIC/PRIVATE INTERFACE
4. Taming Conflict of Interests 29
5. Federally Sponsored Research Under Bayh-Dole 35

PART III INTELLECTUAL PROPERTY AND ITS REGULATION
6. The Anticommons 47
8. Rate Regulation: An Unneeded Swamp 66
10. Socialization of R&D: The Final Swamp  97

---

**PART IV  THE FDA: PURITY, SAFETY, EFFECTIVENESS**

11. The Steady Expansion of FDA Power  109
12. FDA Versus the Individual: Upstream or Downstream Decision Making  113

---

**PART V  PHARMACEUTICAL MARKETING**

14. Getting the Drugs to Market  143
15. Deceptive Marketing  165

---

**PART VI  LIABILITY FOR PHARMACEUTICALS**

16. Tort Preliminaries  185
17. Product Liability for Prescription Drugs: Manufacturing and Design Cases  194
18. The Main Event: Misrepresentation, Overpromotion, and Duty to Warn  202

---

Conclusion: Socialized Medicines  237
Notes  241
Index  273